Compounds > fluorexon
Page last updated: 2024-08-24

fluorexon and Leukemia P388

fluorexon has been researched along with Leukemia P388 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bégu, S; Devoisselle, JM; Mordon, S1
Drinyaev, VA; Ermakova, NV; Korystov, YN; Kruglyak, EB; Kublik, LN; Levitman, MKh; Mosin, VA; Novik, TS; Shaposhnikova, VV; Sterlina, TS1
Bailly, C; Cuevas, C; Kluza, J; Lansiaux, A; Otero, G; Tardy, C; Vanhuyse, M1
Besznyak, I; Diófalvi, K; Jakab, F; Kéri, G; Kopper, L; Kupcsulik, P; Mersich, T; Micsik, T; Mihalik, R; Pap, A; Petak, I; Sarkadi, B; Schafer, E; Schwab, R; Szokolóczi, O; Tihanyi, B; Tihanyi, T; Zarand, A1
Holló, M; Homolya, L; Mechetner, EB; Müller, M; Sarkadi, B1

Other Studies

5 other study(ies) available for fluorexon and Leukemia P388

ArticleYear
Noninvasive fluorescent study in situ and in real time of glucose effects on the pharmacokinetic of calcein.
    Journal of biomedical optics, 2002, Volume: 7, Issue:4

    Topics: Animals; Fluoresceins; Fluorescent Dyes; Glucose; Leukemia P388; Mice; Spectrometry, Fluorescence

2002
Avermectins inhibit multidrug resistance of tumor cells.
    European journal of pharmacology, 2004, Jun-16, Volume: 493, Issue:1-3

    Topics: Animals; Cell Division; Cell Line, Tumor; Cell Survival; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Synergism; Fluoresceins; Fluorescence; Humans; Ivermectin; Leukemia P388; Male; Mice; Paclitaxel; Rhodamine 123; Russia; Vincristine

2004
Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
    Cancer letters, 2005, Apr-28, Volume: 221, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Cycle; Coumarins; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluoresceins; Heterocyclic Compounds, 4 or More Rings; Isoquinolines; Leukemia P388; Membrane Potentials; Mice; Mitochondria; Rhodamine 123; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Verapamil

2005
Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors.
    Assay and drug development technologies, 2007, Volume: 5, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antigens, Surface; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers; Biopsy; Body Fluids; Carcinoma; Cell Separation; Cell Survival; Fluoresceins; Fluorescent Antibody Technique; Humans; Keratins; Leukemia P388; Neoplasms

2007
A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells.
    British journal of cancer, 1996, Volume: 73, Issue:7

    Topics: 3T3 Cells; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blotting, Western; Cell Membrane; Drug Resistance, Multiple; Flow Cytometry; Fluoresceins; Fluorometry; Humans; KB Cells; Leukemia P388; Leukemia, Erythroblastic, Acute; Mice; Multidrug Resistance-Associated Proteins; Neoplasms, Experimental; Verapamil

1996